Cargando…

Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene

[Image: see text] © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Detalles Bibliográficos
Autores principales:	Labandeira‐Garcia, Jose L., Parga, Juan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544027/ https://www.ncbi.nlm.nih.gov/pubmed/35766438 http://dx.doi.org/10.1002/mds.29137

Ejemplares similares

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Neuromelanin‐MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template‐Based Standardized Analysis
por: Xing, Yue, et al.
Publicado: (2022)

Height and nigral neuron density in Parkinson’s disease
por: Saari, Laura, et al.
Publicado: (2022)

Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines
por: Parga, Juan A., et al.
Publicado: (2018)

NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
por: Parga, Juan A., et al.
Publicado: (2021)

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
por: Labandeira, Carmen M., et al.
Publicado: (2022)

Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
por: Benner, Eric J., et al.
Publicado: (2008)

Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons
por: Garrido, Manuel, et al.
Publicado: (2010)

Reversing Parkinson Disease Model with in situ Converted Nigral Neurons
por: Qian, Hao, et al.
Publicado: (2020)

Dose‐dependent effect of mesenchymal stromal cells co‐grafted with dopaminergic neurons in a Parkinson's disease rat model
por: Rodriguez‐Pallares, Jannette, et al.
Publicado: (2021)

Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson’s Disease
por: Guatteo, Ezia, et al.
Publicado: (2022)

NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson’s disease using convolutional neural network
por: Gaurav, Rahul, et al.
Publicado: (2022)

Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson’s disease
por: Hernandez-Chan, Nancy G., et al.
Publicado: (2015)

Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular–Subventricular Zone
por: Garcia-Garrote, Maria, et al.
Publicado: (2019)

Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease
por: Simunovic, Filip, et al.
Publicado: (2010)

An imbalance of netrin‐1 and DCC during nigral degeneration in experimental models and patients with Parkinson's disease
por: Hua, Ye, et al.
Publicado: (2023)

Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease
por: Zarkali, Angeliki, et al.
Publicado: (2021)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

Heptachlor induced nigral dopaminergic neuronal loss and Parkinsonism-like movement deficits in mice
por: Hong, Seokheon, et al.
Publicado: (2014)

Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans
por: Costa-Besada, Maria A., et al.
Publicado: (2017)

Renin angiotensin system and gender differences in dopaminergic degeneration
por: Rodriguez-Perez, Ana I, et al.
Publicado: (2011)

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson’s disease
por: Ayton, Scott, et al.
Publicado: (2014)

Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s disease
por: Chalazonitis, Alcmène, et al.
Publicado: (2022)

Combined cell-based therapy strategies for the treatment of Parkinson’s disease: focus on mesenchymal stromal cells
por: Rodríguez-Pallares, Jannette, et al.
Publicado: (2022)

Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo
por: Leem, Eunju, et al.
Publicado: (2018)

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death
por: Rodriguez-Perez, Ana I., et al.
Publicado: (2018)

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy
por: Engeln, Michel, et al.
Publicado: (2016)

Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset
por: Schierding, William, et al.
Publicado: (2020)

Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin–angiotensin system in the nigra
por: Garrido-Gil, Pablo, et al.
Publicado: (2012)

Angiotensin AT(1) and AT(2) receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia
por: Rivas-Santisteban, Rafael, et al.
Publicado: (2020)

Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinson’s Disease
por: Scholten, Marlieke, et al.
Publicado: (2017)

Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson’s disease
por: Pflug, Christina, et al.
Publicado: (2020)

Nigral volume loss in prodromal, early, and moderate Parkinson’s disease
por: Langley, Jason, et al.
Publicado: (2023)

Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson’s disease
por: Chen, Yupin, et al.
Publicado: (2015)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

The Neuroprotective Mechanism of Low-Frequency rTMS on Nigral Dopaminergic Neurons of Parkinson's Disease Model Mice
por: Dong, Qiaoyun, et al.
Publicado: (2015)

Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction
por: Liu, Zhenhua, et al.
Publicado: (2022)

Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19
por: Rodriguez-Perez, Ana I., et al.
Publicado: (2021)

Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [ (18)F]FMPEP‐d (2)
por: Ajalin, Riikka M., et al.
Publicado: (2022)

Searching for the primary site of motor neuron degeneration in ALS
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jjr0masiin3rci0u5in90hpljr